ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,564.41
      1.08%
      US Tech 100
      19,255.20
      1.29%
      Dow Jones
      40,421.36
      0.33%
      Brent Oil
      81.655
      0.17%
      Bitcoin
      67,499.07
      -0.16%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Viridian Therapeutics Inc (VRDN) Quote

      Viridian Therapeutics Inc

      Viridian Therapeutics Inc (VRDN)

      NASDAQ
      14.98
      0.48
      (3.31%)
      Closed July 22 4:00PM
      Delayed by 15 minutes
      14.50
      -0.48
      (-3.20%)
      After Hours: 7:49PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      14.50
      Bid
      14.53
      Ask
      16.19
      Volume
      987,561
      14.31 Day's Range 15.12
      10.925 52 Week Range 24.18
      Market Cap
      925.426M
      Previous Close
      14.50
      Open
      14.67
      Last Trade
      1
      @
      14.61
      Last Trade Time
      Financial Volume
      $ 14,577,441
      VWAP
      14.7611
      Average Volume (3m)
      1,003,439
      Shares Outstanding
      63,822,468
      Dividend Yield
      -
      PE Ratio
      -4.02
      Earnings Per Share (EPS)
      -3.72
      Revenue
      314k
      Net Profit
      -237.73M

      About Viridian Therapeutics Inc

      Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more

      Sector
      Medical Laboratories
      Industry
      Medical Laboratories
      Website
      www.viridiantherapeutics.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Viridian Therapeutics Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker VRDN. The last closing price for Viridian Therapeutics was $14.50. Over the last year, Viridian Therapeutics shares have traded in a share price range of $ 10.925 to $ 24.18.

      Viridian Therapeutics currently has 63,822,468 shares outstanding. The market capitalization of Viridian Therapeutics is $925.43 million. Viridian Therapeutics has a price to earnings ratio (PE ratio) of -4.02.

      VRDN Latest News

      More News

      Form 8-K - Current report

      July 15 2024
      Edgar (US Regulatory)

      Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

      July 03 2024
      Business Wire

      Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

      - On track to initiate two phase 3 clinical trials of VRDN-003 in August 2024 - - REVEAL-1 and REVEAL-2, will evaluate two active dosing regimens of subcutaneously (SC) administered VRDN-003 in...

      June 11 2024
      Business Wire

      Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

      June 10 2024
      Edgar (US Regulatory)

      Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

      June 06 2024
      Business Wire

      Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

      Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...

      May 31 2024
      Business Wire

      Viridian Therapeutics to Participate in Upcoming May Investor Conferences

      Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...

      May 10 2024
      Business Wire

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 08 2024
      Edgar (US Regulatory)

      Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

      - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024...

      May 08 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.745.3779069767413.7616.9913.76128683515.2290979CS
      41.814.173228346512.716.9911.8590163113.76834119CS
      121.4611.196319018413.0416.9911.4100343913.2600538CS
      26-5.54-27.644710578820.0421.4611.494714015.61952563CS
      52-5.91-28.956393924520.4124.1810.92586851916.44820291CS
      156-2.56-15.005861664717.06399.4758075819.67752604CS
      260-6.89-32.21131369821.39399.4750116519.65776177CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MIRAMIRA Pharmaceuticals Inc
      $ 5.01
      (627.35%)
      		158.14M
      CMAXCareMax Inc
      $ 5.19
      (228.48%)
      		102.64M
      NUKKNukkleus Inc
      $ 0.499
      (55.94%)
      		26.2M
      SNOASonoma Pharmaceuticals Inc
      $ 0.423
      (37.34%)
      		4.88M
      ONDSOndas Holdings Inc
      $ 1.1297
      (34.06%)
      		2.19M
      CGBSCrown LNG Holdings Ltd
      $ 0.9902
      (-29.77%)
      		3.29M
      LGCBLinkage Global Inc
      $ 3.7833
      (-27.45%)
      		166.7k
      SPECSpectaire Holdings Inc
      $ 0.395
      (-24.76%)
      		1.78M
      GSUNGolden Sun Health Technology Group Ltd
      $ 5.07
      (-24.55%)
      		155.37k
      SLNASelina Hospitality PLC
      $ 0.0364
      (-23.04%)
      		75.77M
      NVDANVIDIA Corporation
      $ 123.45
      (4.68%)
      		221.22M
      SQQQProShares UltraPro Short QQQ
      $ 8.08
      (-4.49%)
      		176.65M
      MIRAMIRA Pharmaceuticals Inc
      $ 5.01
      (627.35%)
      		151.42M
      SERVServe Robotics Inc
      $ 8.7192
      (15.49%)
      		148.59M
      NCPLNetcapital Inc
      $ 0.1105
      (6.25%)
      		121.97M

      VRDN Discussion

      View Posts
      Apprentice Apprentice 3 years ago
      I put into it a lot of $
      423 shares!
      👍️0
      Apprentice Apprentice 3 years ago
      It just doesn't want to move above $18
      Yet, it's not diving much either.
      What do you think at this point? Sell temporarily and by later low?
      My average is too high @17.76 !
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.
      👍️0

      Your Recent History

      NASDAQ
      VRDN
      Viridian Therapeutics
      Delayed Upgrade Clock